{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:59:29Z","timestamp":1786132769027,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1681\/asn.2013060585","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T21:34:45Z","timestamp":1392932085000},"page":"837-849","source":"Crossref","is-referenced-by-count":59,"title":["Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch"],"prefix":"10.1681","volume":"25","author":[{"given":"Frank","family":"Weidemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Guerrero","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schelleckes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Reiermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Stypmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Martin","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-24-20230208","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease.","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"R3-24-20230208","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy.","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"R4-24-20230208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial.","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R5-24-20230208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-24-20230208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"R7-24-20230208","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: An analysis of registry data.","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"R8-24-20230208","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial.","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R9-24-20230208","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease.","volume":"152","author":"Wraith","year":"2008","journal-title":"J Pediatr"},{"key":"R10-24-20230208","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).","volume":"14","author":"Tsuboi","year":"2012","journal-title":"Genet Med"},{"key":"R11-24-20230208","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol Genet Metab"},{"key":"R12-24-20230208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/8904_2012_177","article-title":"Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.","volume":"9","author":"Pisani","year":"2013","journal-title":"JIMD Rep"},{"key":"R13-24-20230208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R14-24-20230208","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study.","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"R15-24-20230208","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment.","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"R16-24-20230208","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-24-20230208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R18-24-20230208","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease.","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R19-24-20230208","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"R20-24-20230208","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1681\/ASN.2008111212","article-title":"The case for using albuminuria in staging chronic kidney disease.","volume":"20","author":"Gansevoort","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R21-24-20230208","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.STR.27.11.2033","article-title":"Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects.","volume":"27","author":"Miettinen","year":"1996","journal-title":"Stroke"},{"key":"R22-24-20230208","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1681\/ASN.2006050517","article-title":"Microalbuminuria as an early marker for cardiovascular disease.","volume":"17","author":"de Zeeuw","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R23-24-20230208","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta.","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"R24-24-20230208","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s10545-010-9136-0","article-title":"Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.","volume":"33","author":"Tanaka","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"R25-24-20230208","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: Definitions, mechanisms and clinical implications.","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R26-24-20230208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R27-24-20230208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0304-3959(92)90154-4","article-title":"Grading the severity of chronic pain.","volume":"50","author":"Von Korff","year":"1992","journal-title":"Pain"},{"key":"R28-24-20230208","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2377-11-104","article-title":"A modified score to identify and discriminate neuropathic pain: A study on the German version of the Neuropathic Pain Symptom Inventory (NPSI).","volume":"11","author":"Sommer","year":"2011","journal-title":"BMC Neurol"},{"key":"R29-24-20230208","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","article-title":"Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values.","volume":"123","author":"Rolke","year":"2006","journal-title":"Pain"},{"key":"R30-24-20230208","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-121-12-199412150-00009","article-title":"The chronic fatigue syndrome: A comprehensive approach to its definition and study.","volume":"121","author":"Fukuda","year":"1994","journal-title":"Ann Intern Med"},{"key":"R31-24-20230208","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease.","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol Genet Metab"},{"key":"R32-24-20230208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201404000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:23:51Z","timestamp":1786130631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201404000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2013060585","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}